Public release date: 9-Feb-2012
[ | E-mail | Share ]

Contact: Cathia Falvey
cfalvey@liebertpub.com
914-740-2100
Mary Ann Liebert, Inc./Genetic Engineering News

New Rochelle, NY, February 9, 2012?An automated on/off feature built into insulin pump systems can suspend insulin delivery when it detects low blood glucose levels (via continuous glucose monitoring), significantly reducing the severity and duration of hypoglycemia in individuals with type 1 diabetes, according to a study published in Diabetes Technology & Therapeutics, a peer-reviewed journal from Mary Ann Liebert, Inc. The article is available free online.

In the study, Satish Garg, MD, Editor-in-Chief of Diabetes Technology & Therapeutics and Professor of Medicine and Pediatrics at the University of Colorado Denver, and colleagues from the Barbara Davis Center for Childhood Diabetes (Aurora, CO), Rainier Clinical Research Center (Renten, WA), AMCR Institute, Inc. (Escondido, CA), Stanford University Medical Center (CA), Mills-Peninsula Health Services (San Mateo, CA), and Medtronic Inc. (Northridge, CA) used a regimen of fasting and exercise to induce hypoglycemia in a group of subjects with type 1 diabetes who use insulin pump delivery devices along with continuous glucose monitoring.

They compared the severity and duration of hypoglycemia and the risk of rebound hyperglycemia when the automated "low glucose suspend" feature of the pump was turned on or off. They report their findings in the article "Reduction in Duration of Hypoglycemia by Automatic Suspension of Insulin Delivery: The In-Clinic ASPIRE Study."

"This is the first randomized cross-over trial with an attempt to develop an artificial pancreas," says Dr. Garg.

###

Diabetes Technology & Therapeutics is a monthly peer-reviewed journal that covers new technology and new products for the treatment, monitoring, diagnosis, and prevention of diabetes and its complications. Technologies include noninvasive glucose monitoring, implantable continuous glucose sensors, novel routes of insulin administration, genetic engineering, the artificial pancreas, measures of long-term control, computer applications for case management, telemedicine, the Internet, and new medications. Tables of content and a free sample issue may be viewed online.

Mary Ann Liebert, Inc. is a privately held, fully integrated media company known for establishing authoritative peer-reviewed journals in many promising areas of science and biomedical research, including Journal of Aerosol Medicine and Pulmonary Drug Delivery, Metabolic Syndrome and Related Disorders, Childhood Obesity, and Population Health Management. Its biotechnology trade magazine, Genetic Engineering & Biotechnology News (GEN), was the first in its field and is today the industry's most widely read publication worldwide. A complete list of the firm's 70 journals, books, and newsmagazines is available on our website.

Mary Ann Liebert, Inc. 140 Huguenot St., New Rochelle, NY 10801-5215 http://www.liebertpub.com
Phone: (914) 740-2100 (800) M-LIEBERT Fax: (914) 740-2101

[ | E-mail | Share ]

AAAS and EurekAlert! are not responsible for the accuracy of news releases posted to EurekAlert! by contributing institutions or for the use of any information through the EurekAlert! system.

The rest is here:
Automatic suspension of insulin delivery via insulin pumps reduces hypoglycemia